Provided by Tiger Trade Technology Pte. Ltd.

Regulus Therapeutics

8.16
0.0000
Volume:- -
Turnover:75.91M
Market Cap:564.95M
PE:-11.28
High:8.16
Open:8.16
Low:8.16
Close:8.16
52wk High:8.35
52wk Low:0.8301
Shares:69.23M
Float Shares:52.94M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7233
EPS(LYR):-0.8227
ROE:-53.82%
ROA:-34.23%
PB:8.18
PE(LYR):-9.92

Loading ...

BRIEF-Regulus Therapeutics Enters Into Agreement To Be Acquired By Novartis AG

Reuters
·
Apr 30, 2025

Regulus Therapeutics Inc - Deal Valued up to $1.7 Billion With Contingent Value Right

THOMSON REUTERS
·
Apr 30, 2025

Regulus Therapeutics Enters Into Agreement to Be Acquired by Novartis Ag

THOMSON REUTERS
·
Apr 30, 2025

Regulus Therapeutics Inc : Wells Fargo Raises to Overweight From Equal Weight; Raises Target Price to $6 From $3

THOMSON REUTERS
·
Mar 28, 2025

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 28, 2025

Regulus Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
Mar 28, 2025

Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise

MT Newswires Live
·
Mar 28, 2025

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease

MT Newswires Live
·
Mar 28, 2025

BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Reuters
·
Mar 27, 2025

Regulus Therapeutics Inc -Positive Topline Data From Fourth Cohort of Patients

THOMSON REUTERS
·
Mar 27, 2025

Regulus Therapeutics Inc -on Track for Initiation of Phase 3 Single Pivotal Trial in Q3 2025

THOMSON REUTERS
·
Mar 27, 2025

Regulus Therapeutics-Patients Receiving 300 Mg Farabursen Demonstrated Mean Halting of Height-Adjusted Total Kidney Volume Growth Over 4 Months

THOMSON REUTERS
·
Mar 27, 2025

Regulus Therapeutics Announces Successful Completion of Its Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Farabursen (Rgls8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

THOMSON REUTERS
·
Mar 27, 2025

Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 17, 2025